Lung Cancer Diagnostics Market, by Type (Small Cell Lung Cancer, Non-small Cell Lung Cancer), Test (Imaging Test, Biopsy, Sputum Cytology, Molecular Test, Others): Global Opportunity Analysis and Industry Forecast, 2020-2027

The global lung cancer diagnostics market is estimated to surpass $4,074.0 million by 2027, exhibiting a CAGR of 8.1% from 2020 to 2027.

OFFERINGS OF THE REPORT:

The report offers comprehensive analysis of the global lung cancer diagnostics market by thoroughly studying different aspects of the market including major segments, market statistics, market dynamics, regional market outlook, investment opportunities, and top players working towards the growth of the market.

The report also sheds light on present scenario and upcoming trends and developments that are contributing in the growth of the market. In addition, key market boomers and opportunities driving the market growth are provided in the report. Besides, restraints and challenges that hold power to obstruct the market growth are also profiled in the report. The report also offers Porter’s five forces analysis of the market to elucidate factors such as competitive landscape, bargaining power of buyers and suppliers, threats of new players, and emergence of substitutes in the market.

Based on the key forces molding the market, the report offers future perspective and growth outlook of the global market. The report offers market size and forecast by keenly evaluating every segment of the global lung cancer diagnostics market. Regional market breakdown of these segments is also offered in the report. The report divides the global lung cancer diagnostics market into four main regions including Europe, North America, Asia-Pacific, and LAMEA. Furthermore, these regions are sub-divided to profile detailed panorama of the lung cancer diagnostics market across major countries in specific regions. Moreover, the report reveals some of the recent developments, trends, and forthcoming opportunities in every region.

HIGHLIGHTS OF THE MARKET

• The report offers market size and forecast for the period from 2019 to 2027
• This report highlights trends, innovations, and new developments along with a detailed quantitative analysis of the lung cancer diagnostics market during the period of forecast
• The prevailing and upcoming opportunities along with the tactical assessment of the global lung cancer diagnostics market growth is provided
• The market size and estimations are based on a comprehensive analysis of market drivers and restraints and key innovations in the lung cancer diagnostics market
• Information on leading market players, Porter’s Five Analysis, and top winning business strategies is offered
• The development plans and initiatives undertaken by the top market players are highlighted to understand the competitive landscape of the market

KEY MARKET SEGMENTS

The report segments the global market into type ,test

• Type: Small Cell Lung Cancer, Non-small Cell Lung Cancer

• Test: Imaging Test, Biopsy, Sputum Cytology, Molecular Test, Others

Region:

The global lung cancer diagnostics market is divided into North America, Europe, Asia Pacific, and LAMEA.

The above-mentioned regions are further dived in countries as follows:

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific

• LAMEA
  • Brazil
  • Argentina
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of LAMEA

LEADING PLAYERS OF THE MARKET

The most influential companies are mentioned in the report which include AstraZeneca, Qiagen N.V., Illumina Inc., Janssen and Sanofi S.A.

The report outlines the business overview including financial performance, latest strategic moves & developments, product portfolio, and SWOT analysis of the leading players of the lung cancer diagnostics market.

1. Roche Diagnostics

2. Thermo Fisher Scientific

3. Qiagen N.V.

4. Agilent Technologies

5. AstraZeneca

6. Janssen and Sanofi S.A.

7. bioM